ALA – Arovella Therapeutics Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 2

Company Profile

Arovella Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapies to treat human disease. The Company focuses on two areas oncology and conditions that impact the central nervous system. The Company’s invariant natural killer T (iNKT) cell therapy platform is to treat blood cancers. It is developing the DKK1 monoclonal antibody (mAb) as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. It is developing anagrelide as an approach to the treatment of cancer, applicable across a range of solid tumors. Anagrelide is used to reduce elevated platelets and lower the thrombotic risk in myeloproliferative diseases associated with high platelet counts. Its ZolpiMist, is an oral spray formulation of zolpidem tartrate to treat short-term insomnia is available in cherry-flavored. The Company is also developing OroMist, an oral spray to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Responses